Evidence map›Paper›PMID 31423276›Full record

ArticleOncology letters2019

MicroRNA-2053 overexpression inhibits the development and progression of hepatocellular carcinoma.

Tao Song, Ke Ma, Cui Zhao, Jijin Yang, Jingyu Liu

Open access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Tao SongDepartment of Medical Imaging, Changhai Hospital of Second Military Medical University of Chinese PLA, Shanghai 200433, P.R. China.
Ke MaShandong Co-Innovation Center of Classic TCM Formula, Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250355, P.R. China.
Cui ZhaoDepartment of General Medicine, Affiliated Hospital of Chengde Medical College, Chengde, Hebei 067000, P.R. China.
Jijin YangDepartment of Interventional Radiology, Changhai Hospital of Second Military Medical University of Chinese PLA, Shanghai 200433, P.R. China.
Jingyu LiuDepartment of Interventional Radiology, Changhai Hospital of Second Military Medical University of Chinese PLA, Shanghai 200433, P.R. China.
Changhai Hospital · CNAffiliated Hospital of Chengde Medical College · CNShandong University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNAs (miRNAs) represent a class of small RNAs that participate in the regulation of tumor progression. However, the identification of functional miRNAs in tumors has not been thoroughly elucidated. In the present study we aim to investigate the impact of altered miR-2053 expression in hepatocellular carcinoma (HCC) cells. The results of the present study demonstrated that miR-2053 overexpression inhibited cell proliferation, migration and invasion, and promoted apoptosis in a HCC cell line, while miR-2053 knockdown induced the opposite cellular phenotypic changes. Mechanistically, it was found that overexpression of miR-2053 resulted in the downregulation of the phosphoinositide 3-kinase (PI3K) and Wnt/β-catenin signaling pathways, which are aberrantly expressed in HCC. Collectively, the results indicate that miR-2053 serves as a tumor suppressor with a crucial role in inhibiting the proliferation, migration and invasion of HCC via targeting the PI3K and Wnt/β-catenin signaling pathways. These data indicate a potential application of miR-2053 in cancer therapy.

Indexed as

invasionmicroRNA-2053migrationphosphoinositide 3-kinaseproliferationWnt

Identifiers

PMID31423276
PMCPMC6607194
OpenAlexW2950961430

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.